Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Ortho Regenerative Technologies, Pharmaessentia USA, Pharming Group, Regeneron, Visen.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Akebia, Akoya, Auransa, Bioasis, BMS, Catalyst, Celgene, , Cyclerion, CNS, IGM, Innovent, Kye, Medunik, Pharvaris, Polarisqb, Roche, Surface.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: 4D, Acadia, Advaccine, Albireo, Alzheon, Beyondspring, Galapagos, Gilead, Mirum, Point, Precision, Valbiotis, Valneva, Vincerx, Virios, Zynerba.

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aethlon Medical, Applied UV, Atos, Avricore, Baxter, Cardiac Insight, Caredx, Cigna, Cosmosid, Electromedical Technologies, Eurobio Scientific, Eurofins, GE Healthcare, Grifols, Gynesonics, Harrow Health, Huma, I.signal, Iceni Diagnostics, Invitae, Mhub, Nortech Systems, Novacyt, Novo Healthnet, Novo Integrated Systems, Nucleix, Olympus, Organx, Pamgene, Renalytix AI, RNA Disease Diagnostics, Sandwalk Bioventures, Viet My Instrument and Technology, Visionology.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aavantibio, Afimmune, Alk, Bayer, Bioversys, Corbus, Cynata, Evaxion, Eversana, Glaxosmithkline, Histogen, Hoth, IGM, Immutep, Merck, Mindcure, Mindset, Moderna, Monopar, National, Noria, Ocugen, Organon, Otonomy, Oyster Point, Rain, RDIF, Resverlogix, Tekcyte, Tempus, Wave.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adaptive Phage, Arrowhead, Compass, Edesa, Geneos, Innovation, Kintara, Nanoscope, NIH, Novartis, Oric, PDS, Protalix, Qbiotics, Redx, Replimune, Salvat, Seagen, Tonix, United, Vasopharm, VBL.

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Cognoa, Edwards, Sorrento.

LONDON – Adding to the immediate and obvious toll of serious illness and death, COVID-19 seems likely to be fueling development of resistance to antibiotic drugs, according to the findings of the most comprehensive analysis to date.